New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists | Prostate Cancer and Prostatic Diseases
FDA Approves Relugolix for Advanced Prostate Cancer - NCI
Progress in Clinical Research on Gonadotropin-Releasing Hormone Recept | DDDT
Degarelix - wikidoc
Degarelix Injection
Cancers | Free Full-Text | Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer | HTML
Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer | Future Oncology
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design - ScienceDirect
In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design | JACC: CardioOncology
An efficient synthesis of deuterium‐labeled degarelix acetate, a third‐generation gonadotropin‐releasing hormone receptor antagonist - Huang - 2018 - Journal of Labelled Compounds and Radiopharmaceuticals - Wiley Online Library
GnRH agonists and antagonists in prostate cancer - GaBI Journal
Evaluation of degarelix in the management of prostate cancer. - Abstract - Europe PMC
Degarelix - Wikipedia
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics - European Urology
Mechanism of action of Firmagon ® (Degarelix). | Download Scientific Diagram
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone | Nature Reviews Endocrinology
Firmagon (Degarelix for Injection): Uses, Dosage, Side Effects, Interactions, Warning
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice | Scientific Reports
The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK | SpringerLink
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
Cells | Free Full-Text | Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer | HTML
Degarelix | SpringerLink
Degarelix - wikidoc
Mechanism of action of Firmagon ® (Degarelix). | Download Scientific Diagram
Pharmacological treatment of patients with advanced prostate cancer
